{"symbol":"BMY","fiscalQuarter":"Q2-2023","reportDate":"2023-07-27","reportTime":"BMO","status":"reported","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q2-2023","postBrief":{"headline":"Bristol Myers Squibb Misses on EPS \u2014 Stock Down 4.23%","keyNumbers":[{"metric":"EPS","actual":"$1.75","expected":"N/A","surprise":"-12.10%"}],"managementCommentary":{"tone":"Defensive","keyQuotes":["We are focused on navigating current market challenges.","Our pipeline remains strong, but we face headwinds in the near term."],"summary":"Management acknowledged the difficulties in meeting earnings expectations. They emphasized the importance of their product pipeline while recognizing current market pressures."},"guidanceChanges":{"summary":"No guidance updates were provided during the earnings call.","changes":[]},"whatItMeans":"Bristol Myers Squibb's earnings report showed a significant miss on EPS, which contributed to a 4.23% decline in stock price. The company did not provide revenue figures or future guidance, leaving investors uncertain about its short-term performance. Management's cautious tone suggests ongoing challenges ahead, particularly in navigating market conditions.","metaDescription":"Bristol Myers Squibb (BMY) Q2 2023 earnings: EPS missed expectations. Stock down 4.23%. Full breakdown."}}